Nextcure provides business update and reports full year 2024 financial results

Beltsville, md., march 06, 2025 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported full year 2024 financial results.
NXTC Ratings Summary
NXTC Quant Ranking